Oncorus Inc. (ONCR): Price and Financial Metrics

Oncorus Inc. (ONCR): $0.33

0.01 (+4.69%)

POWR Rating

Component Grades













Add ONCR to Watchlist
Sign Up

Industry: Biotech



in industry

ONCR Stock Price Chart Interactive Chart >

Price chart for ONCR

ONCR Price/Volume Stats

Current price $0.33 52-week high $1.95
Prev. close $0.32 52-week low $0.23
Day low $0.33 Volume 4,625
Day high $0.34 Avg. volume 319,813
50-day MA $0.38 Dividend yield N/A
200-day MA $0.78 Market Cap 8.61M

Oncorus Inc. (ONCR) Company Bio

Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.

ONCR Latest News Stream

Event/Time News Detail
Loading, please wait...

ONCR Latest Social Stream

Loading social stream, please wait...

View Full ONCR Social Stream

Latest ONCR News From Around the Web

Below are the latest news stories about ONCORUS INC that investors may wish to consider to help them evaluate ONCR as an investment opportunity.

10 Companies That Had Tons of Money in SVB When It Collapsed

Silicon Valley Bank is gone but its clients are still here.

Samuel O'Brient on InvestorPlace | March 13, 2023

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and D

Yahoo | January 4, 2023

Cancer biotech cuts staff by one-fifth

Boston biotech Oncorus Inc. is losing one-fifth of its employees as it pauses work on all but one drug. Oncorus (Nasdaq: ONCR) announced the cuts on Wednesday, saying it will lay off 20% of its staff. ONCR-021 is still preclinical, but Oncorus believes it could have applications in non-small cell lung cancer, hepatocellular carcinoma, clear cell renal cell carcinoma and melanoma.

Yahoo | November 30, 2022

Oncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce

Oncorus Inc (NASDAQ: ONCR) is reprioritizing its pipeline and is discontinuing the Phase 1 trial of ONCR-177 to focus resources on ONCR-021. In addition, the company is discontinuing the development of ONCR-177, reducing its workforce and burn rate, and reiterating guidance for its cash runway into early 2024. Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023. Related: Chardan Sees Over 200% Upsid

Yahoo | November 30, 2022

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company’s cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, In

Yahoo | November 30, 2022

Read More 'ONCR' Stories Here

ONCR Price Returns

1-mo -15.58%
3-mo 30.28%
6-mo -61.18%
1-year -81.46%
3-year N/A
5-year N/A
YTD 30.28%
2022 -95.19%
2021 -83.70%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7451 seconds.